The identification of these pathways is consistent with the recent development of therapy for breast cancer, i.e., targeting of ErbB-2 with trastuzumab, and vascular endothelial growth factor (VEGFA) with bevacizumab in combination with chemotherapy has proven to be a milestone in molecular targeted therapy for breast cancer [24]. The gene discussed is VEGFA; the disease is breast carcinoma.